APO Research
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Amyotrophic Lateral Sclerosis (ALS) Industry Growth and Trends Forecast to 2032

20 December 202597 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Amyotrophic Lateral Sclerosis (ALS) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Amyotrophic Lateral Sclerosis (ALS) include Sun Pharma, Sanofi, Lunan Pharma, Mylan Pharma, Mitsubishi Tanabe Pharma, Glemark Generics, Covis Pharma and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Amyotrophic Lateral Sclerosis (ALS) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Amyotrophic Lateral Sclerosis (ALS) market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Amyotrophic Lateral Sclerosis (ALS) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Amyotrophic Lateral Sclerosis (ALS).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Amyotrophic Lateral Sclerosis (ALS) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Amyotrophic Lateral Sclerosis (ALS) Market by Company

Sun Pharma

Sanofi

Lunan Pharma

Mylan Pharma

Mitsubishi Tanabe Pharma

Glemark Generics

Covis Pharma

Apotex

Amyotrophic Lateral Sclerosis (ALS) Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Amyotrophic Lateral Sclerosis (ALS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Riluzole Table 2. Major Company of Edaravone (Radicava) Table 3. Major Company of Other Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Type (2021-2026) Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (US$ Million) Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Type (2021-2026) Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2021-2026) & (US$/unit) Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Type (2027-2032) Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (US$ Million) Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Type (2027-2032) Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2027-2032) & (US$/unit) Table 15. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 16. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 18. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 22. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (US$ Million) Table 25. Amyotrophic Lateral Sclerosis (ALS) Industry Trends Table 26. Amyotrophic Lateral Sclerosis (ALS) Industry Drivers Table 27. Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges Table 28. Amyotrophic Lateral Sclerosis (ALS) Industry Restraints Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Company (2021-2026) Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Company (2021-2026) & (k units) Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Sales Share by Company (2021-2026) Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Market Price by Company (2021-2026) & (US$/unit) Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Amyotrophic Lateral Sclerosis (ALS) Major Company Production Sites and Headquarters Table 36. Global Amyotrophic Lateral Sclerosis (ALS) Company, Product Type & Application Table 37. Global Amyotrophic Lateral Sclerosis (ALS) Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Amyotrophic Lateral Sclerosis (ALS) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026) & (k units) Table 42. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Region (2021-2026) Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026) & (US$ Million) Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Region (2021-2026) Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2027-2032) & (k units) Table 47. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Region (2027-2032) Table 48. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2027-2032) & (US$ Million) Table 49. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Region (2027-2032) Table 50. Global Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 51. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Application (2021-2026) Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (US$ Million) Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Application (2021-2026) Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2021-2026) & (US$/unit) Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 58. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Application (2027-2032) Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (US$ Million) Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Application (2027-2032) Table 61. Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2027-2032) & (US$/unit) Table 62. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 63. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 65. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 69. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (US$ Million) Table 72. Sun Pharma Company Information Table 73. Sun Pharma Business Overview Table 74. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 76. Sun Pharma Recent Development Table 77. Sanofi Company Information Table 78. Sanofi Business Overview Table 79. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 81. Sanofi Recent Development Table 82. Lunan Pharma Company Information Table 83. Lunan Pharma Business Overview Table 84. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 86. Lunan Pharma Recent Development Table 87. Mylan Pharma Company Information Table 88. Mylan Pharma Business Overview Table 89. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 91. Mylan Pharma Recent Development Table 92. Mitsubishi Tanabe Pharma Company Information Table 93. Mitsubishi Tanabe Pharma Business Overview Table 94. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 96. Mitsubishi Tanabe Pharma Recent Development Table 97. Glemark Generics Company Information Table 98. Glemark Generics Business Overview Table 99. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 101. Glemark Generics Recent Development Table 102. Covis Pharma Company Information Table 103. Covis Pharma Business Overview Table 104. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 106. Covis Pharma Recent Development Table 107. Apotex Company Information Table 108. Apotex Business Overview Table 109. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 111. Apotex Recent Development Table 112. North America Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 113. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 114. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2026) Table 115. North America Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032) & (k units) Table 116. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Country (2027-2032) Table 117. North America Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026) & (US$ Million) Table 119. North America Amyotrophic Lateral Sclerosis (ALS) Market Share by Country (2021-2026) Table 120. North America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. North America Amyotrophic Lateral Sclerosis (ALS) Market Share Forecast by Country (2027-2032) Table 122. Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 123. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 124. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2026) Table 125. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032) & (k units) Table 126. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Country (2027-2032) Table 127. Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026) & (US$ Million) Table 129. Europe Amyotrophic Lateral Sclerosis (ALS) Market Share by Country (2021-2026) Table 130. Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Europe Amyotrophic Lateral Sclerosis (ALS) Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 134. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2026) Table 135. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032) & (k units) Table 136. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026) & (US$ Million) Table 139. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share by Country (2021-2026) Table 140. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share Forecast by Country (2027-2032) Table 142. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 143. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 144. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2026) Table 145. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032) & (k units) Table 146. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Country (2027-2032) Table 147. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026) & (US$ Million) Table 149. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share by Country (2021-2026) Table 150. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 154. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2026) Table 155. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032) & (k units) Table 156. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026) & (US$ Million) Table 159. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share by Country (2021-2026) Table 160. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share Forecast by Country (2027-2032) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Amyotrophic Lateral Sclerosis (ALS) Distributors List Table 165. Amyotrophic Lateral Sclerosis (ALS) Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. Amyotrophic Lateral Sclerosis (ALS) Image Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Market Size (2021-2032) & (US$ Million) Figure 4. Global Amyotrophic Lateral Sclerosis (ALS) Sales (2021-2032) & (k units) Figure 5. Riluzole Image Figure 6. Global Riluzole Sales YoY Growth (2021-2032) & (k units) Figure 7. Edaravone (Radicava) Image Figure 8. Global Edaravone (Radicava) Sales YoY Growth (2021-2032) & (k units) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 11. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Type 2025 VS 2032 Figure 13. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Type in 2025 Figure 14. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Type in 2025 Figure 15. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Type in 2025 Figure 16. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Type in 2025 Figure 19. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 27. Drugs Store Image Figure 28. Global Drugs Store Sales YoY Growth (2021-2032) & (k units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Amyotrophic Lateral Sclerosis (ALS) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Application 2025 VS 2032 Figure 33. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Application in 2025 Figure 34. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Application in 2025 Figure 35. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Application in 2025 Figure 36. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Application in 2025 Figure 39. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share in Value by Application in 2025 Figure 43. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Amyotrophic Lateral Sclerosis (ALS) Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Amyotrophic Lateral Sclerosis (ALS) Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Amyotrophic Lateral Sclerosis (ALS) Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Amyotrophic Lateral Sclerosis (ALS) Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Sun Pharma
  • Sanofi
  • Lunan Pharma
  • Mylan Pharma
  • Mitsubishi Tanabe Pharma
  • Glemark Generics
  • Covis Pharma
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Amyotrophic Lateral Sclerosis (ALS) Market by Type
  6. 1.3.1 Riluzole
  7. 1.3.2 Edaravone (Radicava)
  8. 1.3.3 Other
  9. 1.4 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Type
  10. 1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Amyotrophic Lateral Sclerosis (ALS) Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
  2. 2.2 Amyotrophic Lateral Sclerosis (ALS) Industry Drivers
  3. 2.3 Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges
  4. 2.4 Amyotrophic Lateral Sclerosis (ALS) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2026)
  2. 3.2 Global Top Players by Amyotrophic Lateral Sclerosis (ALS) Sales (2021-2026)
  3. 3.3 Global Top Players by Amyotrophic Lateral Sclerosis (ALS) Price (2021-2026)
  4. 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Amyotrophic Lateral Sclerosis (ALS) Major Company Production Sites & Headquarters
  6. 3.6 Global Amyotrophic Lateral Sclerosis (ALS) Company, Product Type & Application
  7. 3.7 Global Amyotrophic Lateral Sclerosis (ALS) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Amyotrophic Lateral Sclerosis (ALS) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Amyotrophic Lateral Sclerosis (ALS) Tier 1, Tier 2, and Tier 3
4 Amyotrophic Lateral Sclerosis (ALS) Regional Status and Outlook
  1. 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Historic Market Size by Region
  3. 4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Amyotrophic Lateral Sclerosis (ALS) Forecasted Market Size by Region
  7. 4.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Amyotrophic Lateral Sclerosis (ALS) by Application
  1. 5.1 Amyotrophic Lateral Sclerosis (ALS) Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Store
  4. 5.1.3 Other
  5. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Application
  6. 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sun Pharma
  2. 6.1.1 Sun Pharma Company Information
  3. 6.1.2 Sun Pharma Business Overview
  4. 6.1.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  6. 6.1.5 Sun Pharma Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Lunan Pharma
  14. 6.3.1 Lunan Pharma Company Information
  15. 6.3.2 Lunan Pharma Business Overview
  16. 6.3.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  18. 6.3.5 Lunan Pharma Recent Developments
  19. 6.4 Mylan Pharma
  20. 6.4.1 Mylan Pharma Company Information
  21. 6.4.2 Mylan Pharma Business Overview
  22. 6.4.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  24. 6.4.5 Mylan Pharma Recent Developments
  25. 6.5 Mitsubishi Tanabe Pharma
  26. 6.5.1 Mitsubishi Tanabe Pharma Company Information
  27. 6.5.2 Mitsubishi Tanabe Pharma Business Overview
  28. 6.5.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  30. 6.5.5 Mitsubishi Tanabe Pharma Recent Developments
  31. 6.6 Glemark Generics
  32. 6.6.1 Glemark Generics Company Information
  33. 6.6.2 Glemark Generics Business Overview
  34. 6.6.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  36. 6.6.5 Glemark Generics Recent Developments
  37. 6.7 Covis Pharma
  38. 6.7.1 Covis Pharma Company Information
  39. 6.7.2 Covis Pharma Business Overview
  40. 6.7.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  42. 6.7.5 Covis Pharma Recent Developments
  43. 6.8 Apotex
  44. 6.8.1 Apotex Company Information
  45. 6.8.2 Apotex Business Overview
  46. 6.8.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  48. 6.8.5 Apotex Recent Developments
7 North America by Country
  1. 7.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country
  2. 7.1.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026)
  4. 7.1.3 North America Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  6. 7.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026)
  8. 7.2.3 North America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country
  2. 8.1.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026)
  4. 8.1.3 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  6. 8.2.1 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country
  2. 9.1.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  6. 9.2.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales by Country
  2. 10.1.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026)
  4. 10.1.3 South America Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  6. 10.2.1 South America Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026)
  8. 10.2.3 South America Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country
  2. 11.1.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
  6. 11.2.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Amyotrophic Lateral Sclerosis (ALS) Value Chain Analysis
  2. 12.1.1 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process
  7. 12.2 Amyotrophic Lateral Sclerosis (ALS) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
  10. 12.2.3 Amyotrophic Lateral Sclerosis (ALS) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst